Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Given Average Rating of “Moderate Buy” by Brokerages

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) has been assigned an average rating of “Moderate Buy” from the eight analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $28.00.

Several equities research analysts have recently issued reports on KMTS shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Kestra Medical Technologies in a research report on Wednesday, October 8th. Wall Street Zen downgraded Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Sunday, September 28th. Finally, BTIG Research initiated coverage on Kestra Medical Technologies in a research report on Tuesday, November 18th. They set a “buy” rating and a $32.00 price objective for the company.

Kestra Medical Technologies Stock Performance

Shares of Kestra Medical Technologies stock opened at $24.07 on Friday. The business has a 50-day simple moving average of $25.45 and a 200-day simple moving average of $20.74. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.84 and a current ratio of 6.84. Kestra Medical Technologies has a one year low of $13.25 and a one year high of $30.00. The company has a market cap of $1.24 billion and a PE ratio of -9.44.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings results on Thursday, September 11th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.16. The firm had revenue of $19.37 million during the quarter, compared to analysts’ expectations of $17.68 million.

Institutional Trading of Kestra Medical Technologies

Institutional investors have recently modified their holdings of the stock. Brown Brothers Harriman & Co. raised its stake in Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after acquiring an additional 656 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Kestra Medical Technologies by 7.3% during the third quarter. Rhumbline Advisers now owns 12,925 shares of the company’s stock worth $307,000 after purchasing an additional 874 shares during the last quarter. Quarry LP acquired a new stake in shares of Kestra Medical Technologies during the first quarter worth about $33,000. BNP Paribas Financial Markets lifted its holdings in shares of Kestra Medical Technologies by 148.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after purchasing an additional 1,638 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of Kestra Medical Technologies in the 3rd quarter valued at about $48,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.